BiotechTube

OPT-302 + Lucentis™

Phase 1Completed
2 views this week 0 watching💤 Quiet
Interest: 23/100
23
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Eye Diseases

Conditions

Eye Diseases, Macular Degeneration, Retinal Diseases, Retinal Degeneration, Neovascularization, Pathologic

Trial Timeline

Jul 1, 2015 → Sep 1, 2017

NCT ID
NCT02543229

About OPT-302 + Lucentis™

OPT-302 + Lucentis™ is a phase 1 stage product being developed by Opthea for Eye Diseases. The current trial status is completed. This product is registered under clinical trial identifier NCT02543229. Target conditions include Eye Diseases, Macular Degeneration, Retinal Diseases.

What happened to similar drugs?

20 of 20 similar drugs in Eye Diseases were approved

Approved (20) Terminated (2) Active (0)
✅Infliximab + Infliximab + InfliximabCelltrionApproved
✅Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statinYuhanApproved
✅Sarpogrelate SR + SarpogrelateYuhanApproved
✅Prasugrel (Crushed tablets) + Prasugrel (Integral tablets)Daiichi SankyoApproved
✅Regadenoson + PlaceboAstellas PharmaApproved
✅mouse nerve growth factorSun PharmaceuticalApproved
✅DesidustatZydus LifesciencesApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02543229Phase 1Completed

Competing Products

20 competing products in Eye Diseases

See all competitors
ProductCompanyStageHype Score
polypill + Usual cardiovascular medicationsDr. Reddy's LaboratoriesPhase 3
37
raloxifene + placeboEli LillyPhase 3
40
LatozinemabAlectorPhase 3
22
RLYB116 for InjectionRallybioPhase 1
19
Prasugrel (CS-747) + ClopidogrelEli LillyPhase 2
35
Infliximab + Infliximab + InfliximabCelltrionApproved
50
CT-P13CelltrionPhase 3
36
Subcutaneous infliximab CT-P13 Remsima®SCCelltrionPre-clinical
22
Lesigercept + PlaceboYuhanPhase 2
42
Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statinYuhanApproved
43
Sarpogrelate SR + SarpogrelateYuhanApproved
43
Prasugrel (Crushed tablets) + Prasugrel (Integral tablets)Daiichi SankyoApproved
43
Mirabegron + Solifenacin succinate + PlaceboAstellas PharmaPhase 2
35
Mirabegron + Solifenacin succinateAstellas PharmaPhase 3
40
ATG (Fresenius Biotech)Astellas PharmaPhase 2
27
TamuslosinAstellas PharmaPhase 3
40
LexiscanAstellas PharmaPhase 2
35
mirabegron 25 mg + mirabegron 50 mg + solifenacin 5 mg + solifenacin 10 mg + mirabegron 25 mg matching placebo + mirabegron 50 mg matching placebo + solifenacin 5 mg matching placebo + solifenacin 10 mg matching placeboAstellas PharmaPhase 3
40
Tacrolimus + Cyclosporine + Mycophenolate mofetil + Methylprednisolone + PrednisoneAstellas PharmaPhase 3
40
TamusulosinAstellas PharmaPhase 3
40